Cargando…

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study

BACKGROUND: Real‐world outcomes of nivolumab treatment for gastric cancer and associated prognostic factors remain unclear; the present study aimed to evaluate both items. METHODS: A total of 278 consecutive patients treated with nivolumab for gastric cancer during 2017‐2019 were enrolled in this mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Sho, Oshima, Yoko, Matsumoto, Yu, Seto, Yasuyuki, Yamashita, Hiroharu, Hayano, Koichi, Kano, Masayuki, Ono, Hidetaka Andrew, Mitsumori, Norio, Fujisaki, Muneharu, Kunisaki, Chikara, Akiyama, Hirotoshi, Endo, Itaru, Ichikawa, Yasushi, Urakami, Hidejiro, Kubo, Hirokazu, Nagaoka, Sakae, Shimada, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560603/ https://www.ncbi.nlm.nih.gov/pubmed/34755011 http://dx.doi.org/10.1002/ags3.12489

Ejemplares similares

Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on long‐term outcomes after gastrectomy
por: Horii, Nobutoshi, et al.
Publicado: (2021)

Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer
por: Tokuhisa, Motohiko, et al.
Publicado: (2015)

Prediction of lymph node metastasis and sentinel node navigation surgery for patients with early-stage gastric cancer
por: Shida, Atsuo, et al.
Publicado: (2016)

Effect of obesity on intraoperative bleeding volume in open gastrectomy with D2 lymph-node dissection for gastric cancer
por: Makino, Hirochika, et al.
Publicado: (2008)

Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
por: Toyota, Satoshi, et al.
Publicado: (2020)

Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
por: Mimura, Kosaku, et al.
Publicado: (2023)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Impact of Tumor Location on the Quality of Life of Patients Undergoing Total or Proximal Gastrectomy
por: Fujisaki, Muneharu, et al.
Publicado: (2022)

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection
por: Fujimura, Taku, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

Lip Ulcer Induced by Nivolumab: A Case Report
por: Sato, Itaru
Publicado: (2021)

Recent progress in the treatment for unresectable biliary tract cancer
por: Endo, Itaru
Publicado: (2023)

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
por: Nakamura, Kenji, et al.
Publicado: (2018)

Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01)
por: Itano, Osamu, et al.
Publicado: (2020)

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
por: Senoo, Satoru, et al.
Publicado: (2018)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2020)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Optimal endoscopic drainage strategy for unresectable malignant hilar biliary obstruction
por: Naitoh, Itaru, et al.
Publicado: (2023)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

A novel risk‐scoring system for predicting lymph node metastasis of rectal neuroendocrine tumors
por: Chida, Keigo, et al.
Publicado: (2020)

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
por: Kobayashi, Tomoko, et al.
Publicado: (2018)

Induction of Foxp3-Expressing Regulatory T-Cells by Donor Blood Transfusion Is Required for Tolerance to Rat Liver Allografts
por: Abe, Yuta, et al.
Publicado: (2009)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

The incidences of metachronous multiple gastric cancer after various types of gastrectomy: analysis of data from a nationwide Japanese survey
por: Kinami, Shinichi, et al.
Publicado: (2020)

Clinical analysis of preoperative deep vein thrombosis risk factors in patients with colorectal cancer: Retrospective observational study
por: Nakagawa, Kazuya, et al.
Publicado: (2019)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
por: Ohsawa, Manato, et al.
Publicado: (2023)

Surgical outcomes in gastroenterological surgery in Japan: Report of National Clinical database 2011–2016
por: Kakeji, Yoshihiro, et al.
Publicado: (2017)

Risk factors for incisional surgical site infection after elective laparoscopic colorectal surgery
por: Chida, Keigo, et al.
Publicado: (2019)

Comparison of the continuation and discontinuation of perioperative antiplatelet therapy in laparoscopic surgery for colorectal cancer: A retrospective, multicenter, observational study (YCOG 1603)
por: Ohya, Hiroki, et al.
Publicado: (2020)

KORTUC, a novel hydrogen peroxide‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer
por: Shimbo, Taiju, et al.
Publicado: (2023)

Complete response of metastatic renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus ipilimumab
por: Hayashida, Michikata, et al.
Publicado: (2022)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

A Case of IgA Vasculitis During Nivolumab Therapy for Renal Cell Carcinoma
por: Nagaoka-Takatori, Asami, et al.
Publicado: (2021)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96gf93s1hvg13ec0tlnih43i7s